<code id='ACB07CB3DD'></code><style id='ACB07CB3DD'></style>
    • <acronym id='ACB07CB3DD'></acronym>
      <center id='ACB07CB3DD'><center id='ACB07CB3DD'><tfoot id='ACB07CB3DD'></tfoot></center><abbr id='ACB07CB3DD'><dir id='ACB07CB3DD'><tfoot id='ACB07CB3DD'></tfoot><noframes id='ACB07CB3DD'>

    • <optgroup id='ACB07CB3DD'><strike id='ACB07CB3DD'><sup id='ACB07CB3DD'></sup></strike><code id='ACB07CB3DD'></code></optgroup>
        1. <b id='ACB07CB3DD'><label id='ACB07CB3DD'><select id='ACB07CB3DD'><dt id='ACB07CB3DD'><span id='ACB07CB3DD'></span></dt></select></label></b><u id='ACB07CB3DD'></u>
          <i id='ACB07CB3DD'><strike id='ACB07CB3DD'><tt id='ACB07CB3DD'><pre id='ACB07CB3DD'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:1
          Richard Burr
          North Carolina Senator Richard Burr received strong support from the biotech sector. Gerry Broome/AP

          WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

          North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

          advertisement

          Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Listen: Who gets the credit for GLP
          Listen: Who gets the credit for GLP

          Whenisnegativedatapositiveenough?Whogetscreditforscientificbreakthroughs?Andwasn’tbiotechsupposedtob

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          STAT Virtual Event: How to Increase Diversity in Clinical Trials

          Editor’snote:Alivestreamoftheeventwillbeembeddedbelowat1p.m.ET. Howdoweensurethepopulationinastudybe